Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Eptifibatide
Drug ID BADD_D00792
Description Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Indications and Usage For treatment of myocardial infarction and acute coronary syndrome.
Marketing Status approved; investigational
ATC Code B01AC16
DrugBank ID DB00063
KEGG ID D06888
MeSH ID D000077542
PubChem ID 448812
TTD Drug ID D09ZIO
NDC Product Code 36974-0068; 52958-001; 25021-409; 52958-040; 67457-630; 70860-303; 14403-0007; 67457-631; 70860-305; 72078-027; 0338-9558; 70436-026; 52958-402; 70436-162; 41524-0002; 55150-220; 67457-629; 70121-1002; 72078-025; 32861-0002; 16729-259; 55150-218; 55150-219; 70121-1003; 70436-027; 70436-163; 52958-128; 16729-260; 72078-026; 25021-408
UNII NA8320J834
Synonyms Eptifibatide | Epifibratide | Epifibatide | 7H-Pyrrolo(2,1-g)(1,2,5,8,11,14,17,20)dithiahexaazacyclotricosine-17-acetic acid, 3-(aminocarbonyl)-11-(4-((aminoiminomethyl)amino)butyl)docosahydro-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-, (3R,11S,17S,20S,25aS)- | Integrilin | Integrelin
Chemical Information
Molecular Formula C35H49N11O9S2
CAS Registry Number 188627-80-7
SMILES C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC (=O)O)CCCCN=C(N)N)C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Retroperitoneal haemorrhage12.01.17.018; 24.07.01.017; 07.07.02.002--
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Thrombocytopenia01.08.01.0020.001036%Not Available
Thrombophlebitis24.01.02.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Mental status changes19.07.01.0010.000082%Not Available
Coronary artery dissection12.02.01.035; 24.02.02.001; 02.02.01.0040.000082%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Haemorrhage24.07.01.0020.000123%Not Available
Angiopathy24.03.02.007--Not Available
Cardiac disorder02.11.01.003--Not Available
Infarction24.04.02.017--Not Available
Blood disorder01.05.01.004--Not Available
Angiogram13.14.08.001--Not Available
Renal impairment20.01.03.010--Not Available
Congenital arterial malformation03.07.09.002; 24.03.03.012--Not Available
Vascular stent thrombosis24.01.01.044; 08.07.05.0020.000288%Not Available
Sotos' syndrome15.11.06.003; 03.11.06.003--Not Available
Mediastinal haematoma24.07.01.074; 22.09.03.0070.000082%Not Available
Spinal subarachnoid haemorrhage24.07.04.037; 12.01.13.010; 17.08.01.0760.000082%Not Available
The 3th Page    First    Pre   3    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene